HeartFlow Analysis vs Tempus ECG-AF
AI Verdict
Choose HeartFlow Analysis if…
Choose HeartFlow Analysis if you need a highly accurate, non-invasive diagnostic solution for assessing coronary artery disease (CAD) severity and blood flow. This tool is ideal for patients who have undergone a CT scan and require detailed, personalized 3D modeling and functional analysis (FFRct) to guide treatment decisions for suspected or known CAD.
View HeartFlow Analysis →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you are looking to proactively identify older patients (65+) at increased risk of developing new-onset atrial fibrillation (AF) within the next year. This AI-powered algorithm leverages standard 12-lead ECGs to support earlier detection and subsequent follow-up for high-risk individuals, enabling timely intervention before AF symptoms manifest.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | HeartFlow Analysis | Tempus ECG-AF |
|---|---|---|
| Pricing | Contact vendor for pricing | Contact vendor |
| Deployment | Cloud-based (AWS) | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
HeartFlow AnalysisHeartFlow Analysis offers a dedicated, intuitive user interface for visualizing and interpreting complex 3D models and FFRct results, supported by educational resources for clinicians to integrate it into their practice. In contrast, Tempus ECG-AF operates primarily as a backend algorithm, integrating via standard protocols without its own user interface, meaning its usability is highly dependent on the host EHR/HIS system.
Clinical Value
HeartFlow AnalysisHeartFlow Analysis boasts extensive clinical validation, including large-scale studies demonstrating high diagnostic accuracy for CAD, significant reduction in invasive procedures, and improved patient management, backed by ACC/AHA guidelines. Tempus ECG-AF provides valuable risk stratification for AF, but its sensitivity is lower (31%), and it is explicitly not intended as a sole diagnostic tool or for patient monitoring.
Pricing & Value
HeartFlow AnalysisHeartFlow Analysis benefits from established Category I CPT codes for both FFRct and Plaque Analysis, indicating broader acceptance and stable reimbursement. Furthermore, studies have demonstrated significant healthcare cost reductions (up to 33%) associated with its use. Tempus ECG-AF has CMS reimbursement with Category III CPT codes, which are temporary, though it does have an established Medicare rate.
Enterprise Readiness
HeartFlow AnalysisBoth tools are FDA cleared, HIPAA compliant, and offer BAAs. However, HeartFlow Analysis explicitly states adherence to leading international standards including HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001, demonstrating a more comprehensive security and quality framework. Its cloud-based (AWS) deployment also suggests robust scalability and it offers resources for building scalable CCTA programs.
Innovation
HeartFlow AnalysisHeartFlow Analysis represents a profound innovation by combining AI, 3D modeling, and computational fluid dynamics to provide non-invasive FFRct and plaque analysis, offering a physiological assessment beyond anatomical stenosis. While Tempus ECG-AF is innovative as the first FDA-cleared AI for AF risk prediction from standard ECGs, HeartFlow's technology involves a deeper and more complex simulation of physiological processes, offering a more transformative shift in diagnostic capabilities.
Support & Docs
HeartFlow AnalysisHeartFlow explicitly offers comprehensive support resources, including clinical, operational, technical, and financial guidance, along with educational series and webinars for effective integration and interpretation. Tempus ECG-AF's available documentation focuses more on technical specifications and intended use, with less explicit mention of broad user support services or training programs.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | HeartFlow Analysis | Tempus ECG-AF |
|---|---|---|
| Name | HeartFlow Analysis | Tempus ECG-AF |
| Company | HeartFlow | Tempus AI, Inc. |
| Primary Function | Provides a non-invasive solution for diagnosing and managing coronary artery disease (CAD) by creating personalized 3D models of patients' coronary arteries from standard CT scans. | Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. |
| Target Patient Population/Use Case | Patients needing diagnosis and management of coronary artery disease (CAD). | Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, for identifying risk of new onset Atrial Fibrillation (AF) within 12 months. |
| Core Technology | AI-powered 3D modeling of coronary arteries, Fractional Flow Reserve derived from CT (FFRct) analysis, Plaque Analysis, Computational Fluid Dynamics (CFD). | AI-based algorithm for 12-lead ECG analysis. |
| Supported Data Input | Standard CT scans | FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems |
Videos
Demos, reviews, and walkthroughs featuring HeartFlow Analysis and Tempus ECG-AF.